EMA Marketing Authorization of New Drugs in February 2026

Why It Matters

The approvals expand therapeutic options for high‑unmet‑need patients and signal strong regulatory confidence in novel mRNA platforms and targeted agents, reshaping competitive dynamics in Europe’s pharma market.

Key Takeaways

• Moderna's mNEXSPIKE shows 9.3% efficacy gain.
• Hansoh's Aumseqa approved for EGFR‑mutated NSCLC.
• Cytokinetics' Myqorzo improves exercise capacity in oHCM.
• ImmunityBio's Anktiva+BCG achieves 71% complete response.
• GSK's Exdensur cuts asthma exacerbations up to 58%

Pulse Analysis

The European Medicines Agency’s February authorisations underscore a pivotal shift toward advanced biologics and precision medicines in the EU. By approving a diverse portfolio—from Moderna’s next‑generation mRNA COVID‑19 vaccine to Hansoh’s third‑generation EGFR inhibitor—the agency highlighted the importance of robust Phase II/III evidence in accelerating market entry. These clear regulatory pathways not only reward innovative trial designs but also set new benchmarks for efficacy and safety that competitors must meet.

Clinically, the new products promise tangible benefits for patients with limited options. mNEXSPIKE demonstrated a 9.3% relative efficacy advantage over Spikevax, while Myqorzo delivered measurable gains in peak oxygen uptake for oHCM sufferers. ImmunityBio’s Anktiva + BCG achieved a 71% complete response rate in BCG‑unresponsive bladder cancer, and Exdensur reduced asthma exacerbations by up to 58%, translating into fewer hospitalisations. Meanwhile, CHMP opinions for Ojemda, Xolremdi, remibrutinib and the combo flu/COVID vaccine mCOMBRIAX broaden therapeutic horizons for pediatric glioma, WHIM syndrome, chronic urticaria and older adults needing dual protection.

Strategically, these approvals reinforce Europe’s role as a launch hub for cutting‑edge therapies, encouraging multinational firms to prioritize EU submissions. The conditional and accelerated pathways signal regulators’ willingness to balance rapid access with post‑marketing commitments, fostering a dynamic environment for future innovations. Companies that can generate compelling Phase III data stand to capture market share quickly, while patients benefit from earlier access to treatments that address previously unmet medical needs.